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Background: The medial temporal region is the earliest affected structure in patients with Alzheimer’s disease 
(AD), and its atrophy is known as the hallmark of AD. This study aimed to investigate the value of medial temporal 
atrophy (MTA) for detecting 18F-florbetaben positron emission tomography (PET)-proven AD pathology.
Methods: We retrospectively enrolled 265 subjects complaining of cognitive decline at a dementia outpatient clinic 
from March 2015 to December 2017. All subjects underwent brain magnetic resonance imaging, 18F-fluorodeoxy-
glucose PET, and 18F-florbetaben PET at baseline. We performed multivariable logistic regression analyses on vari-
ables including age, sex, years of education, white matter hyperintensities, apolipoprotein E (APOE) genotype, and 
memory composite scores in various combinations to investigate whether MTA was indicative of underlying AD 
pathology.
Results: Our sample population of 265 patients comprised 121 with AD-related cognitive impairment, 42 with 
Lewy bodies-related cognitive impairment, 32 with vascular cognitive impairment, and 70 with other or undeter-
mined pathologies. In the multivariable logistic regression analyses, MTA was not an independent predictor of un-
derlying AD pathology (P>0.200). The predictive power of underlying AD-related cognitive impairment significant-
ly increased when multiple variables including APOE genotype and memory composite scores were considered to-
gether (area under the curve >0.750).
Conclusion: Our results suggest that MTA alone may be insufficient to accurately predict the presence of AD pa-
thology. It is necessary to comprehensively consider various other factors such as APOE genotype and a detailed 
memory function to determine whether the patient is at high risk of AD.
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With increasing age, the number of patients visiting primary health 
care facilities due to memory decline has been increasing. The spec-
trum of complaints of memory decline ranges from subjective memo-
ry impairment (SMI) to mild cognitive impairment (MCI) to dementia. 
The clinical significance of SMI and amnestic MCI has been growing, 
as these conditions may represent a transitional state between normal 
cognition and Alzheimer’s disease (AD).1,2) However, not all patients 
progress to AD, and early detection of individuals who are at high risk 
of AD is important to predict prognosis and reduce social burdens.
 The hippocampus is the earliest affected and most vulnerable struc-
ture in AD,3) and medial temporal atrophy (MTA) is known as the hall-
mark of AD. Brain magnetic resonance imaging (MRI) is, therefore, a 
useful screening tool to detect MTA with a predictive value for AD. 
However, hippocampal atrophy can also be observed in various neu-
rodegenerative diseases, such as vascular dementia, dementia with 
Lewy bodies, and Parkinson’s disease.4,5) It is necessary to consider 
whether or not MTA is in fact a specific marker of AD.
 Indeed, several previous studies have reported inconsistent results 
regarding the value of MTA for detecting the prodromal stage of AD6,7) 
and for differentiating AD from other dementias.8) However, these 
studies are limited by the pathologically unproven AD diagnosis; to 
the best of our knowledge, in most of these studies, AD was diagnosed 
based on clinical criteria without any evidence of β-amyloid deposi-
tion from pathological data or on positron emission tomography (PET) 
scans.8-10) Therefore, the aim of this study was to investigate the value 
of MTA for detecting 18F-florbetaben (18F-FBB) PET-proven AD pa-
thology. If MTA can reflect underlying AD pathology, a brain imaging 




We consecutively enrolled 265 patients complaining of cognitive de-
cline at the dementia outpatient clinic, Severance Hospital (Yonsei 
University College of Medicine), from March 2015 to December 2017. 
All subjects underwent a detailed neuropsychological assessment 
(Seoul Neuropsychological Screening Battery [SNSB]) to assess their 
level of cognitive performance.11) To uncover the underlying disease 
that caused the cognitive decline, all subjects underwent brain MRI, 
18F-fludeoxyglucose (18F-FDG) PET, and 18F-FBB PET. Apolipopro-
tein E (APOE) genotyping was performed in 260 patients (five patients 
declined to be genotyped). All subjects also underwent a neurologic 
examination, and 18F-fluorinated N-3-fluoropropyl-2-beta-carboxy-
methoxy-3-beta-(4-iodophenyl) nortropane (18F-FP-CIT) PET scans 
were performed in 132 subjects who showed parkinsonism. 18F-FDG 
PET, 18F-FBB PET, and 18F-FP-CIT PET revealed regional hyper-/hy-
pometabolism, β-amyloid deposition, and nigrostriatal dopaminergic 
degeneration, respectively. All these diagnostic work-up procedures 
were carried out within 6 months, and clinical diagnoses were per-
formed based on the clinical features and neuroimaging findings. This 
study was approved by the Yonsei University Severance Hospital insti-
tutional review board (IRB approval no., 4-2016-0210). The need for 
informed consent was waived because of the retrospective nature of 
the study.
2. Neuropsychological Assessment
The SNSB covers five cognitive domains: attention and working mem-
ory (forward/backward digit span task and letter cancellation test); 
language and related functions (the Korean version of the Boston 
Naming Test, calculation, and praxis); visuospatial function (the Rey 
Complex Figure Test [RCFT] copy and interlocking pentagon); verbal 
and visual memory (immediate recall/delayed recall/recognition test 
using the Seoul Verbal Learning Test [SVLT] for verbal memory; im-
mediate recall/delayed recall/recognition test using the RCFT for visu-
al memory); and frontal/executive function (contrasting program, go/
no-go test, the Controlled Oral Word Association Test, and the Stroop 
test). In addition, the Korean version of the Mini-Mental State Exami-
nation (K-MMSE) was used to assess general cognition. We used z-
scores to assess the level of cognitive performance. A z-score was de-
fined as where the score was positioned in the distribution of scores 
for age- and education-matched normal subjects. The memory com-
posite scores were calculated by dividing the sum of the z-scores by 
the number of tests in the memory function domain.
3. Visual Rating of Medial Temporal Atrophy and White 
Matter Hyperintensities
1) Brain MRI acquisition
MRI scans were acquired using a Philips 3.0 T scanner (Philips Achie-
va; Philips Medical Systema, Best, The Netherlands) with a SENSE 
head coil (SENSE factor=2).
2) Visual rating of MTA
The Scheltens scale was used to rate MTA.12) According to this scale, 
visual assessment of MTA is scored on a scale of 0 (no atrophy) to 4 
(end-stage atrophy). The characteristics of each group were defined as 
the width of the choroid fissure, the width of the temporal horn, and 
the height of the hippocampal formation (Table 1). Then, we used four 
criteria to assess the extent of MTA in each subject. According to crite-
rion 1, the MTA score was calculated by averaging the right and left 
Table 1. Visual rating of medial temporal lobe atrophy
Score Width of choroid fissure Width of temporal horn Height of hippocampus
0 N N N
1 ↑ N N
2 ↑↑ ↑ ↓
3 ↑↑↑ ↑↑ ↓↓
4 ↑↑↑ ↑↑↑ ↓↓↓
N, normal; ↑, increase; ↓, decrease.
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MTA scores for each subject as a continuous variable. For all other cri-
teria, the MTA findings were classified into normal or abnormal ac-
cording to the following cut-off scores: criterion 2: a cut-off score of 1.5 
was used (i.e., an average MTA score equal to or greater than 1.5 was 
regarded as abnormal);13) criterion 3: an age-dependent cut-off score 
(i.e., 3 for subjects ≥75 years old, and 2 for subjects <75 years old, in ei-
ther hemisphere) was used;14) and criterion 4, age was further subdi-
vided using cut-off scores of 1, 1.5, and 2.0 for subjects <65, 65–74, and 
>75 years old, respectively.15)
3) Visual rating of WMHs
The modified Fazekas scale was used to describe the extent of periven-
tricular and deep white matter hyperintensities (WMHs).16) Periven-
tricular WMH was classified as P1 (cap and band <5 mm), P2 (5 mm ≤ 
cap or band <10 mm), or P3 (10 mm ≤ cap or band) and deep WMH 
was classified as D1 (maximum diameter of deep white matter lesion 
<10 mm), D2 (10 mm ≤ lesion <25 mm), or D3 (≥25 mm). We subdi-
vided the subjects into three groups: the minimal ischemia group 
(D1P1 and D1P2), the moderate ischemia group (D1P3, D2P1, D2P2, 
and D2P3), and the severe ischemia group (D3P1, D3P2, and D3P3).17)
4. Visual Assessment of Amyloid Deposition
1) 18F-FBB PET data acquisition
18F-FBB PET scans were performed using Discovery 600 (General 
Electric Healthcare, Milwaukee, MI, USA). The images were acquired 
with a 256×256 matrix 90 minutes after administration of 300 MBq (8 
mCi) FBB for 20 minutes. Then the images were reconstructed with an 
ordered-subsets expectation maximization algorithm in an iso-0.98-
mm voxel size.
2) Visual assessment of 18F-FBB PET images
The regional cortical tracer uptake (RCTU) and brain β-amyloid 
plaque load (BAPL) scoring systems were used to visually assess the 
deposition of β-amyloid.18) The RCTU scoring system grades the tracer 
uptake in the lateral temporal cortex, frontal cortex, posterior cingulate 
cortex/precuneus, and parietal cortex as follows: grade 1, no binding; 
grade 2, minor binding; grade 3, pronounced binding. Based on the 
RCTU scores, the BAPL scoring system classifies the results into 
β-amyloid-negative PET scans (BAPL score 1) and β-amyloid-positive 
PET scans (BAPL scores 2 and 3).
5. Clinical Diagnosis of Alzheimer’s Disease
AD was diagnosed based on both the clinical diagnostic criteria19) and 
the imaging findings on 18F-FDG PET (hypometabolism in AD signa-
ture region of interest)20) and 18F-FBB PET (BAPL scores 2 and 3).21-23)
6. Statistical Analyses
Multivariable logistic regression analyses were performed to investi-
gate whether the MTA and K-MMSE z-scores, which can be easily ob-
tained in primary health care clinics, were predictive of underlying AD 
pathology (model 1). In addition, we performed multivariable logistic 
regression analyses by entering additional variables including age, sex, 
years of education, WMH, APOE genotype, and memory composite 
scores in various combinations. Model 2 included age, sex, years of 
education, WMH, MMSE z-scores, and MTA as variables. Model 3 in-
cluded age, sex, years of education, WMH, APOE genotype, memory 
composite scores, and MTA as variables. The discriminatory power of 
variables was investigated by receiver operating characteristic analy-
ses. A Bootstrap method was used to compare the area under the 
curve (AUC) between the variables. The statistical analyses were per-
Table 2. Demographic characteristics of 265 patients in this study
Characteristic AD (n=121) Non-AD (n=144) P-value
Age (y) 73.31±7.80 73.03±8.27 0.779
Female 75 (62.0) 90 (62.5) 0.931
Education (y) 10.14±5.04 9.04±5.10 0.080
APOE ε4 carrier* 65 (53.7) 33 (22.9) <0.001
Cognitive status 0.008
   Subjective cognitive decline 0 7 (4.9)
   Mild cognitive impairment 57 (47.1) 81 (56.3)
   Dementia  64 (52.9) 56 (38.9)
Korean version of the Mini-Mental State Examination 22.13±4.08 22.99±4.16 0.094
Memory composite score -1.62±0.82 -1.08±0.80 <0.001
Medial temporal atrophy 1.92±0.72 1.75±0.69 0.054
   Right 2.00±0.79 1.78±0.73 0.015
   Left 2.05±0.76 1.93±0.73 0.168
White matter hyperintensities 0.222
   Minimal 52 (43.0) 47 (32.6)
   Moderate 60 (49.6) 84 (58.3)
   Severe 9 (7.4) 13 (9.0)
Values are presented as mean±standard deviation or number (%).
AD, Alzheimer’s disease; APOE, apolipoprotein E.
*One out of 121 patients with AD and four out of 144 patients with non-AD declined to perform APOE genotyping.
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formed with IBM SPSS software ver. 23.0 (IBM Corp., Armonk, NY, 
USA) and R software package ver. 3.4.0 (http://www.r-project.org), and 
a two-tailed P<0.05 was considered significant.
RESULTS
1. Demographic Characteristics
Of the 265 patients, 121 were diagnosed with AD-related cognitive im-
pairment (98 with pure AD pathology and 23 with mixed pathology). 
The other 144 were diagnosed with Lewy bodies-related cognitive im-
pairment (i.e., Parkinson’s disease or dementia with Lewy bodies; 
n=42), vascular cognitive impairment (n=32), other pathologies (i.e., 
epileptic cognitive impairment, tauopathy, normal pressure hydro-
cephalus and others; n=23), and undetermined pathologies (n=47). 
There were no significant differences in age, sex, education, K-MMSE 
scores, and WMHs between the AD and non-AD pathology groups. 
The prevalence of the APOE ε4 allele and dementia were higher in pa-
tients with AD pathology. In addition, the patients with AD-related 
cognitive impairment had lower memory composite scores and tend-
ed to show more severe MTA than those with non-AD pathology (Ta-
ble 2).
2. Association between Medial Temporal Atrophy and 
Alzheimer’s Disease Pathology
Multivariable logistic regression analyses were performed using the 
MTA and K-MMSE z-scores as variables (model 1). The results show 
that MTA was not an independent predictor for the presence of AD 
pathology in patients with cognitive complaints (MTA criterion 1, 
P=0.222; criterion 2, P=0.302; criterion 3, P=0.422; criterion 4, P=0.771) 
(Table 3). The analyses were not powerful enough to differentiate AD-
related cognitive impairment from non-AD-related cognitive impair-
ment; the AUCs were 0.616 (95% confidence interval [CI], 0.549–
0.684), 0.617 (95% CI, 0.549–0.683), 0.618 (95% CI, 0.551–0.686), and 
0.618 (95% CI, 0.551–0.686) for the MTA criteria 1, 2, 3, and 4, respec-
tively (Table 4, Figure 1).
3. Receiver Operating Characteristic Analyses for 
Differentiating Alzheimer’s Disease from Non-Alzheimer’s 
Disease
Additionally, we performed multivariable logistic regression analyses 
by entering additional variables. Model 2 showed again that MTA was 
not an independent predictor for the presence of AD pathology in pa-
tients with cognitive decline (MTA criterion 1, P=0.202; criterion 2, 
P=0.352; criterion 3, P=0.383; criterion 4, P=0.831) (Table 3). This sta-
tistical model did not have enough discriminatory power to discrimi-
nate between AD- and non-AD-related cognitive impairment either 
(AUC, 0.647; 95% CI, 0.580–0.713) for MTA criterion 1, (AUC, 0.644; 
95% CI, 0.578–0.711) for MTA criterion 2, (AUC, 0.644; 95% CI, 0.578–
0.711) for MTA criterion 3, and (AUC, 0.645; 95% CI, 0.578–0.711) for 
MTA criterion 4 (Table 4, Figure 1).
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ence of AD pathology (MTA criterion 1, P=0.686; criterion 2, P=0.732; 
criterion 3, P=0.524; criterion 4, P=0.781) (Table 3). However, this 
model had a fair discriminatory power with AUCs of 0.751 (95% CI, 
0.692–0.810), 0.752 (95% CI, 0.694–0.811), 0.751 (95% CI, 0.692–0.810), 
and 0.751 (95% CI, 0.692–0.809) for MTA criteria 1, 2, 3, and 4, respec-
tively (Table 4, Figure 1). The AUCs for model 3 were significantly 
greater than those for the other models (e.g., for the MTA criterion 4: 
model 1 versus model 2, P=0.963; model 1 versus model 3, P=0.001; 
model 2 versus model 3, P=0.003) (Table 4).
DISCUSSION
The present study investigated whether MTA observed on brain MRI 
scans accurately reflects the underlying AD pathology confirmed by 
18F-FDG PET and 18F-FBB PET scans. The major findings of the study 
were as follows: (1) in the multiple logistic regression analyses, MTA 
was not an independent predictor of underlying AD pathology; and (2) 
the predictive power of the statistical model significantly increased 
(model 3) when multiple variables including age, sex, years of educa-
tion, WMH, APOE genotype, and memory composite scores were 
Table 4. Receiver operating curve analyses in differentiating AD from non-AD
Variable
MTA criteria 1 MTA criteria 2 MTA criteria 3 MTA criteria 4
AUC (95% CI) P-value AUC (95% CI) P-value AUC (95% CI) P-value AUC (95% CI) P-value
Model 1 0.616 (0.549–0.684) 0.034 0.616 (0.549–0.683) 0.034 0.618 (0.551–0.686) 0.035 0.618 (0.551–0.686) 0.034
Model 2 0.647 (0.580–0.713) <0.001 0.644 (0.578–0.711) <0.001 0.644 (0.578–0.711) <0.001 0.645 (0.578–0.711) <0.001
Model 3 0.751 (0.692–0.810) <0.001 0.752 (0.694–0.811) <0.001 0.751 (0.692–0.810) <0.001 0.751 (0.692–0.809) <0.001
1 vs. 2* 0.627 0.726 0.820 0.963
2 vs. 3* 0.003 0.003 0.002 0.003
1 vs. 3* 0.001 <0.001 <0.001 0.001
AD, Alzheimer’s disease; MTA, medial temporal atrophy; AUC, area under the curve; CI, confidence interval.















































































Figure 1. Receiver operating characteristic curves to discriminate between AD-related cognitive impairment and non-AD-related cognitive impairment. (A) MTA criterion 1, (B) 
MTA criterion 2, (C) MTA criterion 3, and (D) MTA criterion 4. The area under the curve for model 3 is significantly greater than that for the other models. AD, Alzheimer’s 
disease; MTA, medial temporal atrophy.
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considered together. However, the statistical model (model 2) includ-
ing age, sex, years of education, WMH, and K-MMSE z-scores as vari-
ables did not predict the underlying AD pathology effectively. These 
findings suggest that K-MMSE and brain imaging studies, which are 
mainly used for screening of dementia in primary health care facilities, 
have a weak predictive power on whether or not the patient’s memory 
decline is caused by AD-related cognitive impairment.
 Dementia is a clinically observable outcome of the cumulative bur-
den of multiple pathological insults in the brain and can result from 
various neurodegenerative disorders (e.g., AD, Parkinson’s disease, 
dementia with Lewy bodies, frontotemporal dementia, and others) as 
well as non-neurodegenerative conditions (e.g., vascular cognitive im-
pairment and vitamin deficiency). It is important to uncover the un-
derlying pathogenesis leading to cognitive decline because the prog-
nosis and therapeutic approach depend on the specific condition. The 
most common pathological condition underlying dementia is AD,24) 
and many patients who visit the outpatient clinic due to cognitive de-
cline would thus like to know if their problems are caused by AD-relat-
ed cognitive impairment. MTA is known as one of the typical features 
of AD,3) and brain MRI scans are, thus, commonly used to reveal the 
underlying AD pathology. In fact, a number of studies on the possibili-
ty of predicting AD by MRI have been conducted,6-10) but the results are 
still controversial.
 The present study demonstrates that the visual rating of MTA on 
brain MRI scans do not provide crucial information in predicting un-
derlying AD pathology. This is probably due to the following reasons. 
(1) MTA is not a specific finding of AD. Previous studies have suggested 
that hippocampal atrophy is also commonly found in healthy elderly 
people,4) particularly in those of advanced age, as well as in patients 
with frontotemporal dementia,25) dementia with Lewy bodies, and 
Parkinson’s disease.5) (2) The structural abnormalities found on brain 
MRI may be minimal to mild in the preclinical stage of AD or amnestic 
MCI. According to Alzheimer’s pathological cascade,26) β-amyloid 
plaque deposition precedes clinical symptoms and reaches a plateau 
by the time clinical symptoms appear. Then, tau-mediated neuronal 
damage and dysfunction occur later, and correlate well with clinical 
symptom severity. Structural abnormalities assessed by brain MRI is 
the last biomarker, and the brain atrophy rate accelerates as patients 
approach dementia. In addition, according to Braak and Braak,27) the 
AD-related neurofibrillary changes occur in six stages: transentorhinal 
stages (stages 1 and 2), limbic stages (stages 3 and 4), and neocortical 
stages (stages 5 and 6). In the transentorhinal stages, the neurodegen-
erative changes in the brain remain below the threshold, which indi-
cates clinical symptoms. The characteristic brain lesions, such as de-
struction of limbic circuits, become evident in the limbic stage. In this 
regard, structural alterations observed on brain MRI alone may be a 
less sensitive tool for detecting underlying AD pathology in patients 
with either SMI or amnestic MCI.
 Model 2, which included age, sex, years of education, and WMH as 
additional variables, did not have enough discriminatory power to 
predict the underlying AD pathology, while model 3, which addition-
ally included APOE genotype and memory composite scores, predict-
ed the underlying AD pathology, regardless of the MTA criteria. The 
APOE ε4 allele is a well-established generic risk factor for late-onset 
AD through both β-amyloid-dependent and β-amyloid-independent 
pathways.28) The prominent memory dysfunction is the pathogno-
monic neuropsychological profile of AD-related cognitive impairment, 
given that early AD pathology frequently affects the neuroanatomical 
networks for episodic memory before other networks.29) Therefore, at 
least a detailed memory function test (i.e., the SVLT and RCFT in the 
SNSB) should be considered in patients who complain of memory de-
cline, to differentiate AD-related cognitive impairment from non-AD-
related cognitive impairment.
 Our study has some limitations. First, selection bias may have oc-
curred when we enrolled the patients with non-AD-related cognitive 
impairment. We retrospectively recruited patients who underwent 
both 18F-FDG PET and 18F-FBB PET to exclude the possibility of un-
derlying AD pathology. These subjects may be more likely to have 
MTA and thus undergo 18F-FBB PET, which might have led to the re-
sults showing that MTA was not an independent predictor for the pres-
ence of AD pathology. Second, this study was based on visual ratings 
of MTA and 18F-FBB uptake, which may be somewhat subjective. An 
objective measurement or quantification of medial temporal volume 
and β-amyloid deposition is needed to confirm our findings in the fu-
ture. Third, although MRI is the preferred imaging modality in the di-
agnostic work-up of cognitive decline, MRI is not available to a num-
ber of patients in primary health care clinics. Instead, brain computed 
tomography can be used as an alternative for MRI, which has been re-
ported to yield reliable information on MTA.30)
 In conclusion, our results suggest that the visual rating of MTA alone 
is insufficient to accurately predict the presence of AD pathology. In 
order to determine whether the patient is at high risk of AD or not, it is 
necessary to comprehensively consider various other factors such as 
APOE genotype and the results of a detailed memory function test.
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